Drug: CTL019 (tisagenlecleucel-T, Novartis)
Status: Granted priority review for the treatment of relapsed and refractory pediatric and young adult patients with B-cell acute lymphoblastic leukemia
Significant Information:
- Investigational chimeric antigen receptor T-cell (CAR-T) therapy
- Based on the results from the Phase II ELIANA study
- 82% (41/50) of patients infused with CAR-T therapy achieved complete remission or complete remission with incomplete blood count recovery at three months